Highly-expressed RIOX2 is associated with a lower overall survival rate in lung cancer patients, without lymph node metastasis or only with proximal lymph node metastasis but it does not predict that of patients with distant lymph node metastasis [21]. Here, RIOX2 is linked to lung carcinoma.